COVID-19: Abnormal liver function tests
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background & Aims Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver test results. Methods Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information on clinical features of patients with abnormal liver tests were collected for analysis. Results Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients having alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels elevated to more than 3× the upper limit of normal, respectively. Patients with abnormal liver tests of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios [ORs] 2.73; 95% CI 1.19–6.3, and 4.44, 95% CI 1.93–10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both p <0.01). Conclusion Patients with abnormal liver tests were at higher risk of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, which should be monitored and evaluated frequently. Lay summary Data on liver tests in patients with COVID-19 are scarce. We observed a high prevalence of liver test abnormalities and liver injury in 417 patients with COVID-19 admitted to our referral center, and the prevalence increased substantially during hospitalization. The presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia. The detrimental effects on liver injury were related to certain medications used during hospitalization, which warrants frequent monitoring and evaluation for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Self-citationA novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Self-citationHoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Self-citationPathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545 · cited 1×
“Additionally, a pathological study of liver biopsy specimens from a patient who died from COVID-19 showed moderate microvesicular steatosis and mild lobular and portal activity, indicating that SARS-CoV-2 may have led to this liver damage.(15) However, little data exists that has comprehensively analyzed other liver e…”
Background
Research works printed but not linked: 3
- Dong, 2019, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, 31, 571
- Meraviglia, 2004, Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation, HIV Med, 5, 334, 10.1111/j.1468-1293.2004.00232.x · doi:10.1111/j.1468-1293.2004.00232.x
- Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, 10.1001/jama.2020.1585 · DOI · Paper page
Cited by
Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China
Cai, Q., Chen, F., Wang, T., Luo, F., Liu, X., Wu, Q., He, Q., Wang, Z., Liu, Y., Liu, L., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0576 · Cited by 706
Self-citationBiomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis
Malik, P., Patel, U., Mehta, D., Patel, N., Kelkar, R., Akrmah, M., Gabrilove, J. L., & Sacks, H. (2021) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2020-111536 · Cited by 618
Sultan, S., Altayar, O., Siddique, S. M., Davitkov, P., Feuerstein, J. D., Lim, J. K., Falck-Ytter, Y., & El-Serag, H. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.001 · Cited by 437
COVID-19: Discovery, diagnostics and drug development
Asselah, T., Durantel, D., Pasmant, E., Lau, G., & Schinazi, R. F. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.031 · Cited by 437
Pathophysiological mechanisms of liver injury in COVID‐19
Nardo, A. D., Schneeweiss‐Gleixner, M., Bakail, M., Dixon, E. D., Lax, S. F., & Trauner, M. (2021) · Liver International · doi:10.1111/liv.14730 · Cited by 397
COVID-19 and liver disease: mechanistic and clinical perspectives
Marjot, T., Webb, G. J., Barritt, A. S., Moon, A. M., Stamataki, Z., Wong, V. W., & Barnes, E. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00426-4 · Cited by 385
Pre‐eclampsia‐like syndrome induced by severe COVID‐19: a prospective observational study
Mendoza, M., Garcia‐Ruiz, I., Maiz, N., Rodo, C., Garcia‐Manau, P., Serrano, B., Lopez‐Martinez, R., Balcells, J., Fernandez‐Hidalgo, N., Carreras, E., et al. (2020) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16339 · Cited by 370
Sarin, S. K., Choudhury, A., Lau, G. K., Zheng, M.-H., Ji, D., Abd-Elsalam, S., Hwang, J., Qi, X., Cua, I. H., Suh, J. I., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10072-8 · Cited by 296
Haimovich, A. D., Ravindra, N. G., Stoytchev, S., Young, H. P., Wilson, F. P., van Dijk, D., Schulz, W. L., & Taylor, R. A. (2020) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2020.07.022 · Cited by 294
Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis
Bertolini, A., van de Peppel, I. P., Bodewes, F. A. J. A., Moshage, H., Fantin, A., Farinati, F., Fiorotto, R., Jonker, J. W., Strazzabosco, M., Verkade, H. J., et al. (2020) · Hepatology · doi:10.1002/hep.31480 · Cited by 293
Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression
Bohn, M. K., Hall, A., Sepiashvili, L., Jung, B., Steele, S., & Adeli, K. (2020) · Physiology · doi:10.1152/physiol.00019.2020 · Cited by 258
Bajaj, J. S., Garcia-Tsao, G., Biggins, S. W., Kamath, P. S., Wong, F., McGeorge, S., Shaw, J., Pearson, M., Chew, M., Fagan, A., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-322118 · Cited by 218
Blood molecular markers associated with COVID‐19 immunopathology and multi‐organ damage
Chen, Y., Zheng, Y., Yu, Y., Wang, Y., Huang, Q., Qian, F., Sun, L., Song, Z., Chen, Z., Feng, J., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020105896 · Cited by 187
Boettler, T., Marjot, T., Newsome, P. N., Mondelli, M. U., Maticic, M., Cordero, E., Jalan, R., Moreau, R., Cornberg, M., & Berg, T. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100169 · Cited by 177
“The prognostic significance of deranged biochemistry in 1 COVID-19 remains unresolved [49]; some groups have demonstrated a strong correlation with 2 duration of hospitalisation, organ failure and intensive care unit admission [37, 41, 50] whilst 3 others have failed to observe any significant associations with outcom…”
Cellular senescence as a potential mediator of COVID‐19 severity in the elderly
Nehme, J., Borghesan, M., Mackedenski, S., Bird, T. G., & Demaria, M. (2020) · Aging Cell · doi:10.1111/acel.13237 · Cited by 94
APASL Covid-19 Task Force, Lau, G., & Sharma, M. (2020) · Hepatology International · doi:10.1007/s12072-020-10054-w · Cited by 88
“6) for developing severe COVID-19 [12].”
BackgroundInfluentialJAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome
Tuttle, K. D., Waugh, K. A., Araya, P., Minter, R., Orlicky, D. J., Ludwig, M., Andrysik, Z., Burchill, M. A., Tamburini, B. A. J., Sempeck, C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108407 · Cited by 72
“We found that serum levels of the enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), two commonly used markers of hepatocyte injury (Cai et al., 2020; Huang et al., 2020; Zhang et al., 2020), were elevated significantly upon P(I:C) treatment in Dp16 mice, reaching concentrations nearly an ord…”
BackgroundSpontaneous portomesenteric thrombosis in a non-cirrhotic patient with SARS-CoV-2 infection
Abeysekera, K. W., Karteszi, H., Clark, A., & Gordon, F. H. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-238906 · Cited by 22
Metadata
- Authors
- Cai, Q., Huang, D., Yu, H., Zhu, Z., Xia, Z., Su, Y., Li, Z., Zhou, G., Gou, J., Qu, J., Sun, Y., Liu, Y., He, Q., Chen, J., Liu, L., & Xu, L.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 73
- Issue
- 3
- Pages
- 566-574
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3015221761
- Cited by
- 1,047
- References
- 31
- FWCI
- 27.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Clinical Research Center for Infectious Diseases (SZSM201612014)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.